- MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 winMapLight Therapeutics’ stock {$MPLT} plummeted more than 60% on Monday after a once-daily regimen of its schizophrenia drug missed the primary endpoint in a mid-stage trial, despite the study’s ove…Endpoints · 16m ago↗ source
- Legend CEO Ying Huang resigns; Carvykti chief named interim leaderLegend Biotech, the developer of the blockbuster cancer therapy Carvykti, is in the market for a new CEO. Ying Huang stepped down Friday after serving as CEO since November 2020, Legend announced…Endpoints · 1h ago↗ source
- Sarepta turns to Michael Severino as CEO, looking to move past recent turmoilSarepta Therapeutics has found its new CEO as it seeks to recover from a calamitous past year. Michael Severino will replace the company’s longtime leader Doug Ingram on Tuesday. Severino joins f…